Syphilis: Stage-Based Penicillin Therapy
Core concept: Syphilis therapy is determined by disease stage, neurologic or ocular findings, and pregnancy status.
Key clinical distinction: A single benzathine penicillin injection is correct for early syphilis but not for late latent disease of unknown duration or neurosyphilis.
Prescribing priority: Stage the infection from history, examination, prior serology, and documented exposure before choosing therapy (Smith & Honeywell, 2026).
Establish diagnosis and stage
Use a treponemal assay and a quantitative nontreponemal test (RPR or VDRL) together in an appropriate diagnostic algorithm. Document pretreatment quantitative titers for follow-up. Primary syphilis can present as a painless ulcer; secondary syphilis can cause rash including palms and soles and systemic symptoms; latent disease lacks clinical manifestations. Without reliable evidence that latent infection occurred within the preceding year, classify as latent syphilis of unknown duration rather than automatically labeling it early. Evaluate vision, hearing, cranial nerves, cognition, and other neurologic symptoms when indicated (Smith & Honeywell, 2026).
Treatment regimens
For primary, secondary, or early latent syphilis, give benzathine penicillin G 2.4 million units IM once. For late latent disease or latent disease of unknown duration, give benzathine penicillin G 2.4 million units IM weekly for three weeks (total 7.2 million units). Neurosyphilis, ocular syphilis, and otosyphilis generally require aqueous crystalline penicillin G 18–24 million units per day IV, divided every four hours or by continuous infusion, for 10–14 days. The repository, formulation, and route matter: benzathine penicillin IM cannot substitute for an IV neurosyphilis regimen (CDC, 2021a, 2021b, 2021c; Smith & Honeywell, 2026).
Penicillin allergy and pregnancy
Doxycycline is an alternative for some nonpregnant patients with early or late latent infection when reliable follow-up is feasible; dosing and duration differ by stage. Penicillin is the only reliably effective treatment for fetal infection prevention in pregnancy. A pregnant patient with syphilis and a true penicillin allergy requires evaluation for desensitization and penicillin treatment rather than substitution with a convenient oral drug. Manage infants exposed during pregnancy using neonatal-specific protocols (CDC, 2021a, 2021d; Smith & Honeywell, 2026).
Follow-up and counseling
Interpret change in nontreponemal titer against the pretreatment titer and timing, not by demanding immediate seronegativity. Follow-up intervals depend on stage and risk; early disease commonly requires reassessment at six and twelve months, while latent disease may require 6-, 12-, and 24-month follow-up. A sustained fourfold increase suggests possible reinfection or treatment failure. Counsel about the transient Jarisch-Herxheimer reaction, partner notification, other STI screening, and public-health reporting. Pregnancy or neurologic symptoms require additional care coordination (Smith & Honeywell, 2026).
Pregnancy and congenital-syphilis prevention
Prenatal syphilis management requires screening at recommended intervals, accurate staging, completion of the correct penicillin regimen, and evaluation for reinfection. For late latent infection or infection of unknown duration during pregnancy, CDC recommends an optimal seven-day interval between benzathine penicillin G doses; an interval longer than nine days requires restarting the entire series. The 10–14-day interval sometimes considered for nonpregnant patients must not be applied in pregnancy. A true penicillin allergy requires desensitization and penicillin rather than substituting doxycycline. Document injection dates, fetal assessment as indicated, and partner services (CDC, 2021a, 2021d; Smith & Honeywell, 2026).
Interpret serology longitudinally
Use a quantitative nontreponemal baseline (eg, RPR 1:16) when treatment begins. Stage depends on symptoms, known exposure, reliable prior tests, and timing—not on the titer magnitude alone. A clinically meaningful response is commonly judged by a fourfold titer change, interpreted in light of stage, treatment history, HIV status, and elapsed follow-up time. Serofast low titers, reinfection, and failure can look similar without longitudinal records (Smith & Honeywell, 2026).
Treatment alternatives require more than an allergy label
Confirm the nature of reported penicillin allergy and stage the infection before selecting alternatives. Doxycycline is an option for selected nonpregnant patients with stage-appropriate duration and reliable follow-up; it is not a substitute for penicillin in pregnancy or neurosyphilis. For late latent syphilis or unknown-duration infection treated with weekly benzathine penicillin, a nonpregnant patient with a delayed dose requires clinical review (10–14 days between injections may be acceptable in some circumstances). During pregnancy, any interval longer than nine days requires restarting the full series. Arrange desensitization when a pregnant patient has a true penicillin allergy (CDC, 2021a, 2021d; Smith & Honeywell, 2026).
Clinical application
A pregnant patient has reactive treponemal testing, RPR 1:32, no documented infection within the preceding year, and a reported immediate penicillin reaction. Unknown-duration latent syphilis calls for three appropriately spaced weekly benzathine penicillin G injections, not a single dose; confirm allergy history and arrange desensitization when needed. Document baseline titer, fetal evaluation per obstetric guidance, the exact return dates, and what to do if an interval is missed. Doxycycline is not a pregnancy fallback (Smith & Honeywell, 2026).
High-yield distinctions
The stage controls duration. Nontreponemal titer magnitude alone does not date infection. Treat pregnant patients with penicillin after desensitization when necessary. Ocular symptoms demand urgent evaluation irrespective of blood titer.
Related YourDNP Resources
Pharmacology learning hub · Gonorrhea · Chlamydia and genital warts · HIV antiretroviral pharmacology
Content last reviewed:
References
Centers for Disease Control and Prevention. (2021a). Latent syphilis. Sexually transmitted infections treatment guidelines. https://www.cdc.gov/std/treatment-guidelines/latent-syphilis.htm
Centers for Disease Control and Prevention. (2021b). Neurosyphilis, ocular syphilis, and otosyphilis. Sexually transmitted infections treatment guidelines. https://www.cdc.gov/std/treatment-guidelines/neurosyphilis.htm
Centers for Disease Control and Prevention. (2021c). P&S syphilis. Sexually transmitted infections treatment guidelines. https://www.cdc.gov/std/treatment-guidelines/p-and-s-syphilis.htm
Centers for Disease Control and Prevention. (2021d). Syphilis during pregnancy. Sexually transmitted infections treatment guidelines. https://www.cdc.gov/std/treatment-guidelines/syphilis-pregnancy.htm
Smith, U. D., & Honeywell, M. S. (2026). Sexually transmitted infections. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 83). McGraw Hill.